Education
About Us
Working with TipRanks
Follow Us
AGNG - ETF AI Analysis
Top Page
Global X Aging Population ETF (AGNG)
Rating:64Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several key holdings, such as AbbVie, AstraZeneca, and Johnson & Johnson, have shown strong year-to-date performance, supporting the ETF's overall returns.
Health Care Focus
The ETF's heavy allocation to the health care sector provides exposure to a stable and growing industry driven by aging population trends.
Consistent Performance
The ETF has delivered steady gains across multiple timeframes, including year-to-date, three months, and one month.
Negative Factors
High Sector Concentration
Nearly 80% of the ETF is allocated to health care, which limits diversification and increases vulnerability to sector-specific risks.
Limited Geographic Diversification
With over 66% of assets concentrated in U.S. companies, the ETF has limited exposure to international markets.
Moderate Expense Ratio
The ETF's expense ratio of 0.5% is higher than some low-cost alternatives, which could slightly reduce net returns over time.
AGNG vs. SPDR S&P 500 ETF (SPY)
AUM71.02M
RegionDeveloped Markets
Expense Ratio0.50%
Beta0.55
IssuerGlobal X
Inception DateMay 09, 2016
Dividend Yield0.81%
Asset ClassEquity
Index TrackedIndxx Aging Population Thematic Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume17,365
30 Day Avg. Volume18,328
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
40.24Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering77
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AGNG Summary
The Global X Aging Population ETF (AGNG) is an investment fund designed to benefit from the growing demand for products and services tailored to older adults. It focuses on companies in healthcare, pharmaceuticals, and senior living, which are well-positioned to serve the needs of aging populations worldwide. Some of its top holdings include well-known companies like Johnson & Johnson and AbbVie. Investors might consider AGNG for long-term growth opportunities tied to this demographic trend. However, it’s important to note that the ETF is heavily concentrated in healthcare, meaning its performance could be impacted by changes in that sector.
How much will it cost me?The Global X Aging Population ETF (AGNG) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed to focus on a specific theme, targeting companies benefiting from the aging population trend.
What would affect this ETF?The Global X Aging Population ETF (AGNG) could benefit from the growing demand for healthcare and senior living services as populations in developed markets age, driving long-term growth for its top holdings like AbbVie and Johnson & Johnson. However, potential risks include regulatory changes in healthcare and real estate sectors or economic downturns that could reduce consumer spending on these services. Interest rate increases may also negatively impact real estate investments within the ETF.
AGNG Top 10 Holdings
The Global X Aging Population ETF is heavily concentrated in healthcare, with names like Eli Lilly, AstraZeneca, and Johnson & Johnson leading the charge. Eli Lilly has been rising steadily, thanks to its robust pipeline and market share gains, while AstraZeneca’s oncology advancements are keeping it on solid footing despite challenges in China. Johnson & Johnson remains a steady performer, bolstered by strategic product launches. However, Regeneron’s mixed signals, including short-term volatility, may be holding the fund back slightly. With its focus on developed markets, this ETF is a clear bet on the growing healthcare needs of aging populations.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ― | 4.20% | $2.96M | ― | ― | ― | |
| Eli Lilly & Co | 3.50% | $2.47M | $996.71B | 36.23% | 72 Outperform | |
| AstraZeneca | 3.39% | $2.39M | $279.88B | 39.02% | 79 Outperform | |
| Johnson & Johnson | 3.36% | $2.37M | $504.27B | 45.30% | 78 Outperform | |
| Welltower | 3.36% | $2.37M | $130.68B | 50.62% | 77 Outperform | |
| Regeneron | 3.22% | $2.27M | $78.44B | 4.92% | 78 Outperform | |
| Roche Holding Ltd | 3.22% | $2.27M | CHF256.01B | 20.83% | 74 Outperform | |
| AbbVie | 3.07% | $2.16M | $395.31B | 29.64% | 66 Neutral | |
| Edwards Lifesciences | 3.06% | $2.16M | $49.51B | 16.52% | 79 Outperform | |
| Merck & Company | 3.00% | $2.11M | $243.91B | 0.85% | 80 Outperform |
AGNG Technical Analysis
Positive
―
Price Trends
35.04
Positive
34.12
Positive
32.66
Positive
Market Momentum
0.23
Positive
54.20
Neutral
41.76
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For AGNG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 36.11, equal to the 50-day MA of 35.04, and equal to the 200-day MA of 32.66, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 54.20 is Neutral, neither overbought nor oversold. The STOCH value of 41.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AGNG.
AGNG Peer Comparison
Comparison Results
Performance Comparison
AGNG
Global X Aging Population ETF
35.82
5.92
19.80%
WISE
Themes Generative Artificial Intelligence ETF
―
―
―
FOWF
Pacer Solactive Whitney Future of Warfare ETF
―
―
―
EFRA
iShares Environmental Infrastructure and Industrials ETF
―
―
―
TINY
ProShares Nanotechnology ETF
―
―
―
KLXY
KraneShares Global Luxury Index ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents